Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis

Author:

Sbidian Emilie123,Chaimani Anna45,Garcia-Doval Ignacio6,Doney Liz7,Dressler Corinna8,Hua Camille13,Hughes Carolyn9,Naldi Luigi10,Afach Sivem3,Le Cleach Laurence13

Affiliation:

1. Department of Dermatology; Hôpital Henri Mondor; Créteil France

2. Clinical Investigation Centre; Hôpital Henri Mondor; Créteil France

3. Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE) - EA 7379; Université Paris Est Créteil (UPEC); Créteil France

4. Université de Paris, Centre of Research in Epidemiology and Statistics (CRESS), INSERM, F-75004; Paris France

5. Cochrane France; Paris France

6. Department of Dermatology; Complexo Hospitalario Universitario de Vigo; Vigo Spain

7. Cochrane Skin, Centre of Evidence Based Dermatology; University of Nottingham; Nottingham UK

8. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin; Berlin Germany

9. c/o Cochrane Skin Group; The University of Nottingham; Nottingham UK

10. Centro Studi GISED (Italian Group for Epidemiologic Research in Dermatology) - FROM (Research Foundation of Ospedale Maggiore Bergamo); Padiglione Mazzoleni - Presidio Ospedaliero Matteo Rota; Bergamo Italy

Publisher

Wiley

Subject

Pharmacology (medical)

Reference1085 articles.

1. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis;Griffiths;New England Journal of Medicine,2010

2. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients;Young;Expert Review of Clinical Immunology,2011

3. Long-term efficacy, safety, and immunogenicity data from a phase III confirmatory study comparing GP2017, a proposed biosimilar, with reference adalimumab;Blauvelt;United European Gastroenterology Journal,2017

4. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches;Blauvelt;British Journal of Dermatology,2018

5. Study to demonstrate equivalent efficacy and to compare safety of biosimilar adalimumab (GP2017) and humira (ADACCESS) clinicaltrials.gov/show/nct02016105

Cited by 66 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3